Halozyme Therapeutics, Inc. (HALO)
67.70
-1.25
(-1.81%)
USD |
NASDAQ |
Dec 30, 16:00
67.51
-0.19
(-0.28%)
After-Hours: 20:00
Halozyme Therapeutics EPS Diluted (Quarterly): 1.432 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Johnson & Johnson | 2.121 |
| Merck & Co., Inc. | 2.316 |
| AIM ImmunoTech, Inc. | -1.569 |
| Bristol Myers Squibb Co. | 1.079 |
| Protalix Biotherapeutics, Inc. | 0.0291 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 175.22M |
| Revenue (Quarterly) | 354.26M |
| Total Expenses (Quarterly) | 179.04M |
| Enterprise Value | 8.770B |
| Gross Profit Margin (Quarterly) | 79.39% |
| Profit Margin (Quarterly) | 49.46% |
| Earnings Yield | 7.03% |
| Operating Earnings Yield | 8.68% |
| Normalized Earnings Yield | 7.027 |